Profits up at Dainippon Sumitomo despite generic competition
This article was originally published in Scrip
Executive Summary
A fall in selling, general and administrative expenses and R&D spending boosted profitability at Dainippon Sumitomo Pharma (DSP) in the first quarter to June 30th, although generic competition hit sales of the firm's top product.